Tscan Therapeutics is trading 5.01% up at $0.41 in pre-market pricing, following a sharp decline earlier in the week; the rebound is unexplained and low confidence.

  • No new company-specific announcement dated September 8, 2026 was identified.
  • September 2’s strategic reorganization includes a pivot toward in vivo solid-tumor therapies, workforce reductions, and pausing further Phase 3 ALLOHA-2 enrollment.
  • The broader market is mixed-to-lower and does not clearly explain the gain.